These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21520048)

  • 1. The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion.
    Selige J; Hatzelmann A; Dunkern T
    J Cell Physiol; 2011 Aug; 226(8):1970-80. PubMed ID: 21520048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition.
    Selige J; Tenor H; Hatzelmann A; Dunkern T
    J Cell Physiol; 2010 May; 223(2):317-26. PubMed ID: 20082309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
    Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
    Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
    Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
    Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
    PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.
    Togo S; Liu X; Wang X; Sugiura H; Kamio K; Kawasaki S; Kobayashi T; Ertl RF; Ahn Y; Holz O; Magnussen H; Fredriksson K; Skold CM; Rennard SI
    Am J Physiol Lung Cell Mol Physiol; 2009 Jun; 296(6):L959-69. PubMed ID: 19304913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D.
    Peter D; Jin SL; Conti M; Hatzelmann A; Zitt C
    J Immunol; 2007 Apr; 178(8):4820-31. PubMed ID: 17404263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase.
    Dunkern TR; Feurstein D; Rossi GA; Sabatini F; Hatzelmann A
    Eur J Pharmacol; 2007 Oct; 572(1):12-22. PubMed ID: 17659276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of type III TGF-β receptor aggravates lung fibrotic process.
    Ahn JY; Park S; Yun YS; Song JY
    Biomed Pharmacother; 2010 Sep; 64(7):472-6. PubMed ID: 20359848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
    Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
    Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
    Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
    Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
    Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
    Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
    Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
    Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of cyclic nucleotide phosphodiesterases 4 in developing rat lung.
    Lopez E; Jarreau PH; Zana E; Franco-Montoya ML; Schmitz T; Evain-Brion D; Bourbon J; Delacourt C; Méhats C
    Dev Dyn; 2010 Sep; 239(9):2470-8. PubMed ID: 20652950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 4 is overexpressed in human keloids and its inhibition reduces fibroblast activation and skin fibrosis.
    Milara J; Ribera P; Marín S; Montero P; Roger I; Tenor H; Cortijo J
    Chem Biol Interact; 2024 Oct; 402():111211. PubMed ID: 39197814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.
    Martin-Chouly CA; Astier A; Jacob C; Pruniaux MP; Bertrand C; Lagente V
    Life Sci; 2004 Jul; 75(7):823-40. PubMed ID: 15183075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The D prostanoid receptor agonist BW245C [(4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid] inhibits fibroblast proliferation and bleomycin-induced lung fibrosis in mice.
    van den Brule S; Wallemme L; Uwambayinema F; Huaux F; Lison D
    J Pharmacol Exp Ther; 2010 Nov; 335(2):472-9. PubMed ID: 20719937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diverse signaling pathways regulate fibroblast differentiation and transformation through Rho kinase activation.
    Harvey KA; Paranavitana CN; Zaloga GP; Siddiqui RA
    J Cell Physiol; 2007 May; 211(2):353-63. PubMed ID: 17167780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
    Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
    Tannheimer SL; Wright CD; Salmon M
    Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.